Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Conditions
Interventions
Certolizumab Pegol
Placebo
Locations
23
United States
Ps0002 203
Phoenix, Arizona, United States
Ps0002 214
Bakersfield, California, United States
Ps0002 212
Santa Monica, California, United States
Ps0002 204
Ormond Beach, Florida, United States
Ps0002 207
Portsmouth, New Hampshire, United States
Ps0002 202
East Windsor, New Jersey, United States
Start Date
December 15, 2014
Primary Completion Date
January 5, 2016
Completion Date
September 12, 2018
Last Updated
October 3, 2019
NCT06857942
NCT06979453
NCT07449234
NCT07116967
NCT07250802
NCT07449702
Lead Sponsor
UCB Biopharma S.P.R.L.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions